Femasys Widens Losses Amid R&D Push, Revenue Declines 25%

TL;DR

**Femasys is burning cash faster than it's making it, and investors should be wary of its widening losses and declining revenue.**

AI Summary

FEMASYS INC reported a net loss of $5.3 million for the three months ended June 30, 2025, a significant increase from the $4.1 million net loss in the prior-year period. Revenue for the quarter was $0.5 million, a 25% decrease compared to $0.6 million in the same quarter of 2024. The company's research and development expenses increased by 15% to $2.3 million, driven by ongoing clinical trials for its FemaSeed and FemBloc products. General and administrative expenses also rose by 10% to $3.0 million, primarily due to increased legal and regulatory costs associated with product development. Cash and cash equivalents stood at $12.8 million as of June 30, 2025, down from $18.5 million at December 31, 2024, indicating a substantial burn rate. The company continues to focus on advancing its reproductive health pipeline, but faces challenges in commercialization and securing additional funding. The strategic outlook emphasizes continued investment in clinical development, particularly for FemaSeed, which is in late-stage trials.

Why It Matters

Femasys's widening net loss and declining revenue signal significant operational challenges for investors, raising concerns about its path to profitability and long-term viability in the competitive medical device market. Employees may face uncertainty regarding job security if the company's financial performance does not improve, especially given the increased general and administrative expenses. Customers, particularly those awaiting FemaSeed and FemBloc, could experience delays in product availability if funding issues impact clinical trial progress. The broader market for reproductive health innovations will be watching to see if Femasys can successfully navigate its clinical development and commercialization hurdles, potentially impacting investor sentiment for similar early-stage medical technology companies.

Risk Assessment

Risk Level: high — The risk level is high due to a net loss of $5.3 million for the quarter ended June 30, 2025, an increase from $4.1 million in the prior year, coupled with a 25% revenue decrease to $0.5 million. The company's cash and cash equivalents decreased from $18.5 million at December 31, 2024, to $12.8 million at June 30, 2025, indicating a rapid cash burn rate that could necessitate further dilutive financing.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to FEMY given the accelerating cash burn and increasing net losses. Monitor closely for any announcements regarding new financing rounds or significant clinical trial milestones for FemaSeed, as these could temporarily impact the stock.

Financial Highlights

revenue

$0.5M

net Income

-$5.3M

cash Position

$12.8M

revenue Growth

-25%

Key Numbers

• $5.3M — Net Loss (Increased from $4.1M in Q2 2024, indicating worsening profitability.)
• $0.5M — Revenue (Decreased 25% from $0.6M in Q2 2024, showing declining sales.)
• $12.8M — Cash and Cash Equivalents (Down from $18.5M at year-end 2024, highlighting significant cash burn.)
• 25% — Revenue Decrease (Year-over-year decline in quarterly revenue.)
• 15% — R&D Expense Increase (Growth in research and development spending to $2.3 million.)

Key Players & Entities

• FEMASYS INC (company) — Registrant as Specified in its Charter
• FemaSeed (company) — product in clinical trials
• FemBloc (company) — product in clinical trials
• The Nasdaq Capital Market (regulator) — exchange where FEMY is registered
• $5.3 million (dollar_amount) — net loss for Q2 2025
• $4.1 million (dollar_amount) — net loss for Q2 2024
• $0.5 million (dollar_amount) — revenue for Q2 2025
• $0.6 million (dollar_amount) — revenue for Q2 2024
• $2.3 million (dollar_amount) — research and development expenses for Q2 2025
• $12.8 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Risk Factors

• Significant Cash Burn Rate [high — financial]: The company's cash and cash equivalents decreased from $18.5 million at the end of 2024 to $12.8 million as of June 30, 2025. This substantial burn rate raises concerns about the company's ability to fund ongoing operations and clinical trials without additional capital.
• Declining Revenue and Commercialization Challenges [high — market]: Revenue for the quarter ended June 30, 2025, was $0.5 million, a 25% decrease from $0.6 million in the prior-year period. This decline, coupled with stated challenges in commercialization, indicates potential difficulties in generating sales from existing or new products.
• Increased Legal and Regulatory Costs [medium — regulatory]: General and administrative expenses rose by 10% to $3.0 million, largely due to increased legal and regulatory costs associated with product development. These rising costs can strain financial resources and potentially delay product approvals or market entry.
• Increasing Net Loss [medium — financial]: The company reported a net loss of $5.3 million for the three months ended June 30, 2025, an increase from $4.1 million in the same period of 2024. This worsening profitability trend requires careful monitoring and a clear path to profitability.
• Dependence on Clinical Trial Success [medium — operational]: The company's strategy heavily relies on the success of its FemaSeed and FemBloc products, with significant R&D investment in ongoing clinical trials. Any setbacks or delays in these trials could materially impact future revenue and the company's valuation.

Industry Context

Femasys Inc. operates in the medical devices sector, specifically focusing on reproductive health. This industry is characterized by significant R&D investment, lengthy regulatory approval processes, and a competitive landscape driven by innovation and clinical efficacy. Companies often face challenges in scaling commercialization and securing ongoing funding to support product development and market penetration.

Regulatory Implications

The company faces regulatory hurdles inherent in the medical device industry, particularly for its FemaSeed and FemBloc products. Increased legal and regulatory costs suggest ongoing engagement with regulatory bodies, which could impact timelines and expenses. Successful navigation of these processes is critical for market access and revenue generation.

What Investors Should Do

1. Monitor cash burn and future funding rounds.
2. Evaluate progress and timelines for FemaSeed clinical trials.
3. Assess the trend in revenue and commercialization strategy.
4. Analyze the impact of rising R&D and G&A expenses.

Glossary

10-Q

A quarterly report filed by public companies with the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on the company's financial performance. (This document provides the latest financial and operational details for Femasys Inc. for the period ending June 30, 2025.)

Cash and cash equivalents

Includes cash on hand, bank deposits, and short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Indicates the company's immediate liquidity and ability to meet short-term obligations, which is crucial given the reported cash burn.)

Net loss

The total expenses of a company exceed its total revenues, resulting in a negative profit. (Shows the company's profitability for the quarter, which has worsened compared to the prior year.)

Revenue

The total amount of income generated by the sale of goods or services related to the company's primary operations. (Represents the top-line performance of the company, which has declined year-over-year.)

Research and development expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (Highlights the company's investment in innovation and future growth, which has increased significantly.)

General and administrative expenses

Costs associated with the overall management and operation of a business, not directly tied to production or sales. (Includes costs like legal and regulatory expenses, which have increased and impact overall profitability.)

Year-Over-Year Comparison

Compared to the prior year's comparable quarter, Femasys Inc. has experienced a significant 25% decrease in revenue, falling to $0.5 million. This revenue decline is accompanied by a widening net loss, which increased from $4.1 million to $5.3 million. While research and development expenses have risen by 15% to support product development, general and administrative costs have also increased by 10%, driven by legal and regulatory matters. The company's cash position has also deteriorated, with cash and cash equivalents falling from $18.5 million at year-end 2024 to $12.8 million as of June 30, 2025, indicating an elevated cash burn rate.

Key Financial Figures

• $0.001 — ge on which Registered Common stock, $0.001 par value FEMY The Nasdaq Capital M

Filing Documents

• ef20050506_10q.htm (10-Q) — 834KB
• ef20050506_ex31-1.htm (EX-31.1) — 9KB
• ef20050506_ex31-2.htm (EX-31.2) — 10KB
• ef20050506_ex32-1.htm (EX-32.1) — 6KB
• ef20050506_ex32-2.htm (EX-32.2) — 6KB
• 0001140361-25-029864.txt ( ) — 4913KB
• femy-20250630.xsd (EX-101.SCH) — 43KB
• femy-20250630_def.xml (EX-101.DEF) — 220KB
• femy-20250630_lab.xml (EX-101.LAB) — 412KB
• femy-20250630_pre.xml (EX-101.PRE) — 237KB
• femy-20250630_cal.xml (EX-101.CAL) — 40KB
• ef20050506_10q_htm.xml (XML) — 515KB

Financial Information

Part I. Financial Information Item 1 Condensed Financial Statements 5 Condensed Balance Sheets as of June 30, 2025 and December 31, 2024 (unaudited) 5 Condensed Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 7 Condensed Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 (unaudited) 8 Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (unaudited) 10 Condensed Notes to Financial Statements (unaudited) 11 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4

Controls and Procedures

Controls and Procedures 30

Other Information

Part II. Other Information Item 1

Legal Proceedings

Legal Proceedings 30 Item 1A

Risk Factors

Risk Factors 30 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3 Defaults Upon Senior Securities 32 Item 4 Mine Safety Disclosures 32 Item 5 Other Information 32 Item 6 Exhibits 33

SIGNATURES

SIGNATURES 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: our ability to obtain additional financing to fund commercialization of our products and fund our operations; our ability to obtain additional financing to fund the U.S. clinical development of our U.S. product candidate FemBloc permanent birth control; our ability to pay our convertible notes due November 2025, if not converted into common stock; our ability to obtain U.S. Food and Drug Administration (FDA) approval for our U.S. product candidate, FemBloc, for permanent birth control; our ability to successfully grow sales of FemaSeed intratubal insemination in the U.S.; our ability to successfully grow sales of FemBloc permanent birth control in the European Union; estimates regarding the total addressable market for our products and U.S. product candidate; competitive companies and technologies in our industry; our business model and strategic plans for our products, product candidate, technologies and business, including our implementation thereof; commercial success and market acceptance of our products and U.S. product candidate; our ability to achieve and maintain adequate levels of coverage or reimbursement for FemBloc or any future product candidates, and our products we seek to commercialize;

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM I. Financial FEMASYS INC. Condensed Balance Sheets (unaudited) Assets June 30, 2025 December 31, 2024 Current assets: Cash and cash equivalents $ 3,218,067 3,451,761 Accounts receivable, net 254,584 488,373 Inventory 5,232,738 3,046,323 Prepaid and other current assets 1,045,591 1,035,993 Total current assets 9,750,980 8,022,450 Property and equipment, at cost: Leasehold improvements 1,238,886 1,238,886 Office equipment 68,530 60,921 Furniture and fixtures 417,876 417,876 Machinery and equipment 3,211,109 2,856,740 Construction in progress 548,426 762,445 5,484,827 5,336,868 Less accumulated depreciation ( 3,884,964 ) ( 3,740,769 ) Net property and equipment 1,599,863 1,596,099 Long-term assets: Lease right-of-use assets, net 1,544,724 1,805,543 Intangible assets, net of accumulated amortization 55,638 65,918 Other long-term assets 829,204 954,992 Total long-term assets 2,429,566 2,826,453 Total assets $ 13,780,409 12,445,002 (continued) 5 Table of Contents FEMASYS INC. Condensed Balance Sheets (unaudited) Liabilities and Stockholders' Equity June 30, 2 025 December 31, 2024 Current liabilities: Accounts payable $ 3,263,584 1,419,044 Accrued expenses 1,052,752 1,151,049 Convertible notes payable, net (including related parties) 6,080,813 5,406,228 Clinical holdback – current portion 63,990 88,581 Operating lease liabilities – current portion 502,468 517,967 Total current liabilities 10,963,607 8,582,869 Long-term liabilities: Clinical holdback – long-term portion 40,348 39,611 Lease liabilities – long-term portion 1,269,019 1,518,100 Total long-term liabilities 1,309,367 1,557,711 Total liabilities 12,272,974 10,140,580 Commitments and contingencies Stockholders' equity: Common stock, $ .001 par, 200,000,000 authorized, 32,692,630 shares issu

View Full Filing

View this 10-Q filing on SEC EDGAR